De Paolantonio Ernest Robert 4

Accession 0000899243-18-009681

CIK 0001103021other

View on SEC.gov Company Profile

Filed

Apr 5, 8:00 PM ET

Accepted

Apr 6, 6:01 PM ET

Size

28.8 KB

Accession

0000899243-18-009681

Insider Transaction Report

Form 4

Period: 2018-04-03

BIODELIVERY SCIENCES INTERNATIONAL INCBDSI

De Paolantonio Ernest Robert

CFO and Secretary

Transactions

Award
Common Stock
2018-04-03+1,267→ 97,731 total
Exercise/Conversion
Common Stock
2018-04-03+34,391→ 132,122 total
Exercise/Conversion
Common Stock
2018-04-03+30,000→ 162,122 total
Exercise/Conversion
Common Stock
2018-04-03+31,667→ 193,789 total
Exercise/Conversion
Common Stock
2018-04-03+27,075→ 220,864 total
Sale
Common Stock
2018-04-05$2.12/sh−30,900$65,508→ 189,864 total
Sale
Common Stock
2018-04-06$2.06/sh−33,255$68,505→ 156,709 total
Award
Restricted Stock Units
2018-04-03−1,267→ 0 total
Exercise: $0.00Exp: 2018-04-03→ Common Stock (1,267 underlying)
Exercise/Conversion
Restricted Stock Units
2018-04-03−34,391→ 0 total
Exercise: $0.00Exp: 2018-04-03→ Common Stock (34,391 underlying)
Exercise/Conversion
Restricted Stock Units
2018-04-03−30,000→ 30,000 total
Exercise: $0.00Exp: 2019-03-01→ Common Stock (30,000 underlying)
Exercise/Conversion
Restricted Stock Units
2018-04-03−31,667→ 63,333 total
Exercise: $0.00Exp: 2020-02-06→ Common Stock (31,667 underlying)
Award
Restricted Stock Units
2018-04-03−27,075→ 0 total
Exercise: $0.00Exp: 2020-02-06→ Common Stock (27,075 underlying)

Footnotes (8)

[F1]The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long-Term Incentive Plan.
[F2]The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended (the "EIP"). Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock.
[F3]The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs that were granted to the Reporting Person on February 29, 2016, pursuant to a grant under the EIP. The remainder of the RSUs under this grant will vest on March 1, 2019.
[F4]The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 6, 2017 under the EIP. The remainder of the RSUs under this grant will vest in equal portions after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020.
[F5]The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the performance-based RSUs ("Performance RSUs") granted to the Reporting Person on February 6, 2017 under the EIP subject to certain performance measures. The remainder of the Performance RSUs under this grant will vest, in equal amounts, but subject to certain performance measures, after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020.
[F6]The shares of common stock were sold by the Reporting Person upon expiration of a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's additional tax liability upon the vesting of the Reporting Person's RSUs.
[F7]On April 5, 2018, the Reporting Person sold an aggregate of 30,900 shares of the Issuer's Common Stock at a weighted average price of $2.12 per share. The highest sale price for the Common Stock was $2.15 per share and the lowest sale price was $2.08 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F8]On April 6, 2018, the Reporting Person sold an aggregate of 33,255 shares of the Issuer's Common Stock at a weighted average price of $2.06 per share. The highest sale price for the Common Stock was $2.15 per share and the lowest sale price was $2.00 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

BIODELIVERY SCIENCES INTERNATIONAL INC

CIK 0001103021

→

Entity typeother

Related Parties

filerCIK 0001588538

Filing Metadata

Form type: 4
Filed: Apr 5, 8:00 PM ET
Accepted: Apr 6, 6:01 PM ET
Size: 28.8 KB

View on SEC.gov